WallStSmart
SPRO

Spero Therapeutics Inc

NASDAQ: SPRO · HEALTHCARE · BIOTECHNOLOGY

$2.51
-0.79% today

Updated 2026-04-30

Market cap
$154.60M
P/E ratio
17.80
P/S ratio
2.31x
EPS (TTM)
$0.15
Dividend yield
52W range
$1 – $3
Volume
0.4M

Spero Therapeutics Inc (SPRO) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20152016201720182019202020212022202320242025
Revenue$0.00$335000.00$1.98M$3.97M$4.74M$9.33M$3.07M$48.58M$103.78M$47.98M$59.62M
Revenue growth (YoY)+490.7%+100.4%+19.6%+96.8%-67.1%+1482.4%+113.6%-53.8%+24.3%
Cost of revenue$11000.00$26.33M$32.87M$33.88M$65.78M$67.00M$1.12M$1.55M$51.44M$96.76M
Gross profit$-11000.00$-26.00M$1.98M$3.97M$4.74M$9.33M$3.07M$48.58M$52.34M$-48.78M$59.62M
Gross margin-7760.6%100.0%100.0%100.0%100.0%100.0%100.0%50.4%-101.7%100.0%
R&D$11.13M$26.33M$32.87M$33.88M$65.78M$67.00M$64.53M$47.59M$51.44M$96.76M$38.47M
SG&A$2.20M$7.22M$10.84M$12.89M$15.59M$21.44M$41.70M$36.48M$24.99M$22.91M$21.18M
Operating income$-13.33M$-33.22M$-41.73M$-42.81M$-63.22M$-79.11M$-87.97M$-42.20M$21.48M$-73.36M$-24000.00
Operating margin-9916.7%-2108.6%-1079.3%-1333.1%-847.9%-2865.5%-86.9%20.7%-152.9%-0.0%
EBITDA$-13.32M$-32.94M$-41.37M$-42.40M$-62.47M$-78.35M$-87.17M$-42.94M$27.15M$-72.48M$-24000.00
EBITDA margin-9833.4%-2090.3%-1069.0%-1317.3%-839.8%-2839.4%-88.4%26.2%-151.1%-0.0%
EBIT$-13.33M$-33.22M$-41.73M$-42.81M$-63.22M$-79.11M$-87.82M$-43.81M$26.79M$-72.48M
Interest expense$0.00$0.00$303000.00$303000.00$0.00$0.00$1.94M$2.60M$0.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-10.15M$-25.49M$-46.10M$-41.66M$-60.17M$-77.52M$-89.76M$-46.41M$22.81M$-68.57M$8.57M
Net income growth (YoY)-151.0%-80.8%+9.6%-44.4%-28.8%-15.8%+48.3%+149.1%-400.6%+112.5%
Profit margin-7609.3%-2329.3%-1050.5%-1269.0%-830.9%-2923.6%-95.5%22.0%-142.9%14.4%